Successes and failures of uterine leiomyoma drug discovery

Mohamed Ali, Zunir Tayyeb Chaudhry, Ayman Al-Hendy

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: To-date, the only cure for symptomatic uterine fibroids (UFs) is surgical intervention. However, surgery may eliminate the hope of future pregnancies; moreover, the intrinsic risks of surgery make it a less favorable to women with UFs. Because of this, conservative medical therapies have become an attractive and prior option for those women. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) agonist, is the only pharmacological agent currently approved for the short-term and pre-operative management of symptomatic UFs in the USA. Areas covered: This systematic review covers the successes and failures of prominent drugs that have been researched for UFs in the past and agents that have shown promise in recent clinical trials. The most recent clinical trials and advances in drug therapy are presented in a comprehensive overview outlining the direction UF drug discovery is heading. Expert opinion: Experts in the field are already on the forefront leading the responsibility to uncover potential drugs as long term fertility friendly viable options for non-invasive treatment/prevention of UFs. Indeed, a shift in the UF management is expected in the future.

Original languageEnglish (US)
Pages (from-to)169-177
Number of pages9
JournalExpert Opinion on Drug Discovery
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Leiomyoma
Drug Discovery
Clinical Trials
Leuprolide
Expert Testimony
Gonadotropin-Releasing Hormone
Pharmaceutical Preparations
Fertility
Pharmacology
Drug Therapy
Pregnancy

Keywords

  • GnRH agonist
  • GnRH antagonist
  • SPRMs
  • Uterine fibroids
  • fertility preservation
  • leiomyoma
  • medical myomectomy
  • prevention
  • treatment
  • vitamin D analogs

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Successes and failures of uterine leiomyoma drug discovery. / Ali, Mohamed; Chaudhry, Zunir Tayyeb; Al-Hendy, Ayman.

In: Expert Opinion on Drug Discovery, Vol. 13, No. 2, 01.02.2018, p. 169-177.

Research output: Contribution to journalReview article

Ali, Mohamed ; Chaudhry, Zunir Tayyeb ; Al-Hendy, Ayman. / Successes and failures of uterine leiomyoma drug discovery. In: Expert Opinion on Drug Discovery. 2018 ; Vol. 13, No. 2. pp. 169-177.
@article{00acb0528bbd45a1bcdd3659e9e31098,
title = "Successes and failures of uterine leiomyoma drug discovery",
abstract = "Introduction: To-date, the only cure for symptomatic uterine fibroids (UFs) is surgical intervention. However, surgery may eliminate the hope of future pregnancies; moreover, the intrinsic risks of surgery make it a less favorable to women with UFs. Because of this, conservative medical therapies have become an attractive and prior option for those women. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) agonist, is the only pharmacological agent currently approved for the short-term and pre-operative management of symptomatic UFs in the USA. Areas covered: This systematic review covers the successes and failures of prominent drugs that have been researched for UFs in the past and agents that have shown promise in recent clinical trials. The most recent clinical trials and advances in drug therapy are presented in a comprehensive overview outlining the direction UF drug discovery is heading. Expert opinion: Experts in the field are already on the forefront leading the responsibility to uncover potential drugs as long term fertility friendly viable options for non-invasive treatment/prevention of UFs. Indeed, a shift in the UF management is expected in the future.",
keywords = "GnRH agonist, GnRH antagonist, SPRMs, Uterine fibroids, fertility preservation, leiomyoma, medical myomectomy, prevention, treatment, vitamin D analogs",
author = "Mohamed Ali and Chaudhry, {Zunir Tayyeb} and Ayman Al-Hendy",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/17460441.2018.1417381",
language = "English (US)",
volume = "13",
pages = "169--177",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Successes and failures of uterine leiomyoma drug discovery

AU - Ali, Mohamed

AU - Chaudhry, Zunir Tayyeb

AU - Al-Hendy, Ayman

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: To-date, the only cure for symptomatic uterine fibroids (UFs) is surgical intervention. However, surgery may eliminate the hope of future pregnancies; moreover, the intrinsic risks of surgery make it a less favorable to women with UFs. Because of this, conservative medical therapies have become an attractive and prior option for those women. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) agonist, is the only pharmacological agent currently approved for the short-term and pre-operative management of symptomatic UFs in the USA. Areas covered: This systematic review covers the successes and failures of prominent drugs that have been researched for UFs in the past and agents that have shown promise in recent clinical trials. The most recent clinical trials and advances in drug therapy are presented in a comprehensive overview outlining the direction UF drug discovery is heading. Expert opinion: Experts in the field are already on the forefront leading the responsibility to uncover potential drugs as long term fertility friendly viable options for non-invasive treatment/prevention of UFs. Indeed, a shift in the UF management is expected in the future.

AB - Introduction: To-date, the only cure for symptomatic uterine fibroids (UFs) is surgical intervention. However, surgery may eliminate the hope of future pregnancies; moreover, the intrinsic risks of surgery make it a less favorable to women with UFs. Because of this, conservative medical therapies have become an attractive and prior option for those women. Leuprolide acetate (LA), a gonadotropin-releasing hormone (GnRH) agonist, is the only pharmacological agent currently approved for the short-term and pre-operative management of symptomatic UFs in the USA. Areas covered: This systematic review covers the successes and failures of prominent drugs that have been researched for UFs in the past and agents that have shown promise in recent clinical trials. The most recent clinical trials and advances in drug therapy are presented in a comprehensive overview outlining the direction UF drug discovery is heading. Expert opinion: Experts in the field are already on the forefront leading the responsibility to uncover potential drugs as long term fertility friendly viable options for non-invasive treatment/prevention of UFs. Indeed, a shift in the UF management is expected in the future.

KW - GnRH agonist

KW - GnRH antagonist

KW - SPRMs

KW - Uterine fibroids

KW - fertility preservation

KW - leiomyoma

KW - medical myomectomy

KW - prevention

KW - treatment

KW - vitamin D analogs

UR - http://www.scopus.com/inward/record.url?scp=85041217818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041217818&partnerID=8YFLogxK

U2 - 10.1080/17460441.2018.1417381

DO - 10.1080/17460441.2018.1417381

M3 - Review article

VL - 13

SP - 169

EP - 177

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 2

ER -